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Introduction
Schizophrenia is a psychiatric disorder that 
affects thought processes and causes mental 
and social function disorders. Characteristics 
of schizophrenia symptoms are divided into 
three groups, including positive symptoms 
such as delusions and hallucinations; 
negative symptoms such as blunted affect and 
apathetic; and cognitive symptoms such as 
attention and memory disorders.1 The World 
Health Organization (WHO) data shows the 
range of schizophrenic patients in the world 
is 21 million people,2 and the Basic Health 
Research (Riset Kesehatan Dasar, Riskesdas) 
data shows the proportion of households 
with schizophrenia or psychosis in Indonesia 
is about seven per 1000 population.3 The 
etiology of schizophrenia is still unknown. 
The current hypothesis explains that the 
manifestations of schizophrenia occur due to 
abnormalities or pathophysiological changes 
in the transmission of neurotransmitters, such 
as dopamine and glutamate, in the central 
nervous system. Mesolimbic and mesocortical 
dopaminergic pathways are responsible for 
manifesting positive symptoms, negative 
symptoms, and cognitive symptoms. The rate of 
glutamate release can affect the dopaminergic 
pathways through the cortico-brainstem 
glutamate pathways. Increased glutamate 
release influences the rate of dopamine release 
which can trigger the clinical symptoms of 
schizophrenia.4 Glutamate transmission can 
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Abstract
Background: Vitamin D is an immune-regulator that influences the neuro-inflammation process in 
schizophrenia. The study aimed to explore the vitamin D serum level in schizophrenic patients at the 
outpatient clinic of the Provincial Mental Hospital, West Java, Indonesia.
Methods: A quantitative descriptive study was conducted in November–December 2019 using 
secondary data of all-male schizophrenic patients at the Provincial Mental Hospital. Data collected 
were demographic characteristics, clinical characteristics, and vitamin D Level. Scoring was then 
performed using Positive and Negative Syndrome Scale (PANSS) and Montreal Cognitive Assessment 
(MoCA) to assess the positive and negative symptoms as well as the cognitive symptoms based on the 
serum vitamin D levels. 
Results: All male schizophrenic patients had a low serum vitamin D level (mean16.67±5.6ng/ml) with 
64.52% of them had vitamin D deficiency (<20 ng/ml). Interestingly, patients with vitamin D deficiency 
had a negative symptom (mean22.1±5.6ng/ml) whereas those with vitamin D insufficiency (20-29 ng/
ml) had a positive symptom (mean 18.55±5.6ng/ml). Furthermore, patients with vitamin D deficiency 
had a lower impaired cognitive function value (mean 19.7±3.4ng/ml) compared to those with vitamin 
D insufficiency.
Conclusions: A low vitamin D serum level in schizophrenic patients may play a role in the pathogenesis 
of this disorder. Further studies are needed to confirm this finding.
Keywords: Montreal cognitive assessment, positive and negative Syndrome scale, schizophrenia, 
       vitamin D
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be influenced by several things, one of which 
is NMDA receptor hypofunction caused by the 
neuroinflammation process.5 Vitamin D which 
functions as an immune-regulator is thought 
influence the neuroinflammation process 
in schizophrenia.6 Risk factors for vitamin 
D deficiency such as geographic location, 
BMI, age, and prenatal infections were also 
found to be related to the risk of developing 
schizophrenia.7
Vitamin D is a fat-soluble steroid hormone 
obtained from the synthesis of pro-vitamin 
D in the skin with the help of exposure to 
ultraviolet light and food intake. Vitamin D 
has two forms according to the source, namely 
vitamin D3 and vitamin D2. Both forms must 
undergo two hydroxylation processes to 
become active form 1.25(OH)2D.8 Besides 
having a role in bone metabolism and calcium 
homeostasis, vitamin D also plays a role in the 
function and development of the brain and 
immune system. Researchers have found that 
the central nervous system can synthesize and 
metabolize vitamin D. Vitamin D receptors 
and enzymes that play a role in vitamin D 
metabolism are found scattered in various 
regions of the brain such as the hippocampus, 
cortex, and limbic system.9 There are various 
psychiatric disorders, such as Alzheimer’s, 
mood disorders, major depression, and 
psychosis or schizophrenia reported to have 
involvement with vitamin D.10
Research conducted in Europe in 
schizophrenia patients with the first psychosis 
episode showed that all patients had lower 
vitamin D levels than controls.11 Another 
study in Medan, North Sumatra found a lower 
mean serum vitamin D level than normal 
levels among schizophrenia patients from the 
Batak tribe.12 Various studies have found a 
decrease in vitamin D levels in schizophrenic 
patients, but no similar studies yet in West 
Java. Therefore, this study aimed to explore 
the vitamin D levels in schizophrenia patients 
in West Java Province.
Methods
This was quantitative descriptive research 
conducted in November-December 2019. In 
total, 31 schizophrenic patients data who 
met the inclusion criteria were collected, 
such as age 18−45 years, male, used atypical 
antipsychotic drugs, could speak Indonesian, 
and both patients and families signed a 
written consent letter to participate in the 
Table 1 Demographic Characteristic of Subjects
Characteristics Subjects (n=31)n(%)
Age (years)
     Mean± SD 35.23 ± 6.8
     Median 36
     Range 24−45
Education
     Elementary School 6 (19.35)
     Junior High School 3 (9.68)
     Senior High School/Vocational High School 20 (64.52)
     College 2 (6.45)
Marital Status
     Not Married 22 (71.97)
     Married 8 (25.8)
     Divorced 1 (3.22)
Occupation
     Working 19 (61.29)
     Unemployed 12 (38.71)
Notes: n=frequency, SD=Standard Deviation
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study. The exclusion criteria were intellectual 
disability, anxiety and uncooperative, and the 
use of psychotropic drugs other than a typical 
antipshychotics. The study protocol was 
granted by the Research Ethics Committee 
Universitas Padjadjaran, number 1350/UN6.
KEP/EC/2019.
The vitamin D 25(OH)D serum levels were 
measured using an electro chemiluminescence 
immunoassay analyzer (ECLIA) and classified 
into normal (>30 ng/ml), insufficiency (20–29 
ng/ml), and the deficiency (<20 ng/ml). The 
assessment of positive and negative symptoms 
was carried out based on the Positive and 
Negative Syndrome Scale (PANSS) to assess the 
severity of seven domains of each symptom. 
A value of one indicated no symptoms and a 
value of seven indicated extreme symptoms. 
Domain with a value of three or greater 
indicated symptom manifestations. Cognitive 
function disorders were classified based on 
the total score from the Montreal Cognitive 
Assessment (MoCA) with a score of >26 
indicated no cognitive impairment, and a 
score of <26 indicated a cognitive impairment. 
The scores then adjusted to the patient’s 
educational history by adding a value of one 
to patients with an education of less than four 
years. The data was presented in the form 
of tables that were valued for frequency and 
percentage (IBM SPSS Statistics software).
Results
Of 31 schizophrenic patients, the mean age was 
35.23 (SD + 6.82; range 24−45 years). The last 
educational history was predominantly high 
school or equivalent (64.52%), already had a 
Table 2 Clinical Characteristics of Subjects
Characteristics Subjects (n=31)n(%)
Age of Onset (years)
     Mean±SD 24.87±6.5
     Median 23
     Range 8−41
Body Mass Index (kg/m2)
     Mean± SD 22.56±3.3
     <18.5 (Underweight) 3 (9.68)
     18.5–24.9 (Normal) 23 (74.19)
     25.5–29.9 (Overweight) 4 (12.9)
     ≥30.0 (Obese) 1 (3.22)
Antipsychotics Used
     Clozapine, Risperidone, Trihexyphenidyl 22 (70.94)
     Risperidone, Trihexyphenidyl 9 (29.03)
Serum Vitamin D Levels (ng/ml)
     Mean±SD 16.67±5.6
     Median 16.76
     Range 8.02−27.75
PANSS Positive Symptoms
     Mean±SD 17±6
PANSS Negative Symptoms
     Mean±SD 21±6
MoCACognitive Symptoms
     Mean±SD 20±4
Notes: PANSS=positive and negative syndrome scale, n=frequency, SD=Standard Deviation
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job (61.29%), but not married yet (71.92%) 
(Table 1). 
The age of onset of the subjects was found 
to be quite young (mean 24.87+6.5 years). 
Most subjects had a normal body mass index 
(74.19%) and used clozapine, risperidone, 
and trihexyphenidyl (70.94%) as the 
antipsychotics. Mean serum vitamin D levels 
showed decreased levels compared to normal 
(16.67±5.6). The average value of PANSS and 
MoCA showed that almost all subjects had a 
mean positive symptoms value of 17±6, mean 
negative symptoms value of 21±6, and mean 
cognitive symptoms of 20±4 (Table 2). 
Serum vitamin D levels of all of the subjects 
were found to be lower than normal levels 
and most had vitamin D deficiency (64.52%) 
as depicted in Table 3. In Table 4, the subjects 
with vitamin D deficiency hade higher negative 
symptom (22.1±5.6) and lower cognitive 
impairment values (19.7±3.4), while subjects 
with vitamin D insufficiency had a higher 
positive symptom value (18.55±5.6).
Discussions
In this study, all schizophrenia patients have 
low serum vitamin D levels, similar to research 
conducted in the United Kingdom, showing 
that schizophrenia patients have a low serum 
vitamin D level.11,13 This result is also similar 
in other parts of Indonesia, in Medan and 
Surabaya.12,14 The decrease of serum vitamin D 
levels in the study might be caused by several 
factors such as lack of sun exposure, lack 
of intake of foods containing vitamin D, the 
presence of genetic factors that affect vitamin D 
metabolism, and possible drug interactions.15
The findings regarding low vitamin D levels 
support the hypothesis of the role of vitamin D 
in the pathogenesis of schizophrenia. Vitamin 
D has a function in the immune system and 
inflammation as a regulator of activation, 
proliferation, and differentiation of immune 
and inflammatory cells. This function enables 
vitamin D to reduce the production of type 
1 pro-inflammatory cytokines and increase 
the production of type 2 anti-inflammatory 
cytokines. In vitamin D deficiency, regulation 
of the immune and inflammatory systems 
mediated by vitamin D is disrupted, causing an 
imbalance in inflammatory cytokine levels and 
increasing pro-inflammatory cytokines.6 
Type 2 immune responses initiated by 
inflammatory cytokines can inhibit indoleamine 
2,3-dioxygenase (IDO) enzyme from the 
metabolism of tryptophan/kynurenine. The IDO 
enzyme functions as a regulator of tryptophan/
kynurenine metabolism by converting 
tryptophan to kynurenine, then kynurenine can 
produce neuroactive metabolites of kynurenic 
acid with the help of the enzyme kynurenine 
aminotransferase. Kynurenic acid is a natural 
antagonist for N-methyl-D-Aspartate (NMDA) 
receptors. The NMDA receptor is one of the 
ionotropic receptors used by glutamate. 
Increased NMDA receptor antagonisms 
cause hypofunction of the receptor, leading 
Table 3 Serum Vitamin D Levels
Serum Vitamin D Levels(ng/ml) Subjects (n = 31)n(%)
Insufficiency 11 (35.48)
Deficiency 20 (64.52)
Table 4 PANSS and MoCA Scoring based on Serum Vitamin D Levels
PANSS and MoCA Scoring
Serum Vitamin D Levels
Insufficiency (n=11) Deficiency (n=20)
PANSS
     Positive Symptoms 18.55±5.6 15.95±6.6
     Negative Symptoms 19.55±5.7 22.1±5.6
MoCA
     Cognitive Symptoms 20.45±3.9 19.7±3.4
Note: PANSS=Positive and Negative Syndrome Scale;MoCA, Montreal Cognitive Assessment;SD, Standard Deviation
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to increased glutamate release. The excess 
release of glutamate can affect the activity of 
the dopaminergic pathway and the release of 
dopamine.5
Physiologically, dopamine works through 
several dopaminergic pathways. Pathways that 
play a role in the pathogenesis of schizophrenia 
are mesolimbic and mesocortical pathways. 
In the mesolimbic pathway, dopamine is sent 
from the ventral tegmental area to the nucleus 
accumbens, which functions in the regulation 
of emotional behavior. In the mesocortical 
pathway, dopamine sent from the ventral 
tegmental area to the prefrontal cortex, 
especially in the dorsolateral region. High 
glutamate release in the ventral tegmental area 
results in the increased mesolimbic pathway 
and decreased mesocortical pathway activity. 
Increased mesolimbic activity is thought to 
cause positive symptoms such as delusions and 
hallucinations, whereas decreased dopamine 
release in the mesocortical pathway is thought 
to cause negative symptoms and cognitive 
symptoms.4
In this study, the PANSS value of negative 
symptoms was higher in patients with vitamin 
D deficiency. This is in accordance with a 
study in Turkey that found patients with 
vitamin D deficiency had higher negative 
symptom values than patients with vitamin D 
insufficiency.7 This study also found subjects 
with vitamin D deficiency experience impaired 
cognitive function with a low MoCA value. 
This finding is in accordance with a study in 
Norway which found schizophrenia patients 
with vitamin D deficiency had cognitive 
impairment.16 Excessive reduction of serum 
vitamin D levels in vitamin D deficiency 
increased the release of excess glutamate and 
dopamine. These conditions further reduce the 
release of dopamine into the prefrontal cortex, 
thereby increasing the severity of negative and 
cognitive symptoms in patients.
The PANSS value of positive symptoms in 
this study was found to be higher in patients 
with vitamin D insufficiency. However, our 
result is not in accordance with research 
conducted in Turkey7 which found that the 
value of positive symptoms (SAPS) was higher 
in patients with vitamin D deficiency. Our study 
is an outpatient schizophrenic patient who 
has received atypical antipsychotic therapy 
so that the patient has experienced a decrease 
in positive symptoms. A typical antipsychotic 
therapy has dopamine receptor antagonistic 
properties so it works by reducing the level 
of dopamine release in the brain. The effects 
of antipsychotic therapy are more effective in 
dealing with positive symptoms than negative 
and cognitive symptoms. Antipsychotic 
therapy can also affect the body’s metabolism, 
but no findings of the interactions between 
antipsychotic drugs and serum vitamin D 
levels.
The limitation of this study is that our 
patients are outpatients who have received 
atypical antipsychotic therapy and some of 
them get additional clozapine therapy. Further 
research is needed with data that are more 
complete to eliminate confounding factors for 
serum vitamin D levels.
To conclude, all schizophrenic patients have 
low serum vitamin D levels. Schizophrenic 
patients with vitamin D deficiency have higher 
negative symptom values and lower cognitive 
impairment values, whereas schizophrenia 
patients with vitamin D insufficiency have 
higher positive symptom values.
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